Literature DB >> 12707704

[Significance of stereotactic biopsy for the management of WHO grade II supratentorial glioma].

A Muacevic1, F W Kreth.   

Abstract

OBJECTIVE: The aim of this prospective study was to compare the diagnostic value of magnetic resonance imaging (MRI) and stereotactic biopsy in patients harboring WHO grade II gliomas.
METHODS: Stereotactic biopsy was performed in 62 adult patients with low-signal, nonenhancing, space-occupying lesions on T1 MR imaging between 1998 and 2001. The results of histological analysis were compared to the preoperative imaging diagnoses. Any adverse perioperative sequel was considered as morbidity. Applied treatment strategies are described.
RESULTS: Transient perioperative morbidity for the stereotactic approach was 4.8% (three patients), and there was no mortality or permanent morbidity. In four patients, neoplastic lesions could be excluded (gliosis: three patients, encephalitis: one), and WHO grade III gliomas were seen in five patients (14.8.% false positive rate of neurodiagnostic imaging). The diagnostic reliability of stereotactic biopsy was 96.8%. The following treatment strategies were initiated: microsurgery (17 patients), interstitial radiosurgery (12 patients), combination of microsurgery and interstitial radiosurgery (21 patients), external beam irradiation (six patients),and chemotherapy (two patients). Four patients were initially not treated.
CONCLUSIONS: Diagnostic neuroimaging is not sufficient for the planning of rational treatment strategies in patients harboring WHO grade II gliomas. Frame-based stereotactic biopsy is a prerequisite for individualized treatment strategies.

Entities:  

Mesh:

Year:  2003        PMID: 12707704     DOI: 10.1007/s00115-003-1487-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  1 in total

1.  [Hereditary diffuse leukencephalopathy with spheroids: a microgliopathy due to CSF1 receptor impairment].

Authors:  M Schuberth; J Levin; D Sawalhe; R Schwarzkopf; L von Baumgarten; B Ertl-Wagner; A Rominger; T Arzberger; H A Kretzschmar; T Froböse; J Diehl-Schmid; S Biskup; A Danek
Journal:  Nervenarzt       Date:  2014-04       Impact factor: 1.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.